ACHV - Achieve Life Sciences gains after late-stage data for smoking cessation agent

Announcing topline data from its Phase 3 ORCA-2 trial for cytisinicline, the clinical-stage biotech, Achieve Life Sciences (NASDAQ:ACHV) announced on Wednesday that those who received its experimental nicotine addiction therapy were 6-8x were more likley to quit smoking compared to placebo. The U.S.-based trial involving 810 adult smokers was designed to study the potential of 3 times daily doses of cytisinicline as a treatment for smoking cessation over a period of 6-weeks or 12-weeks. The study has indicated statistical significance for primary endpoints defined as “biochemically verified continuous abstinence measured during the last 4 weeks of treatment,” the company said. Accordingly, those who received cytisinicline for 12 weeks have indicated 6.3 times higher odds or likelihood to quit smoking during the last four weeks of treatment, compared to those who received the placebo. There were statistically significant results for secondary endpoints: Continuous abstinence over 24 weeks after the treatment. From

For further details see:

Achieve Life Sciences gains after late-stage data for smoking cessation agent